Avista Healthcare Public Acquisition Corp. Announces Merger Agreement
by Kristi Marvin on 2018-08-20 at 12:38pm

(The post below is an excerpt from the weekly subscriber email sent out every Monday morning before the market open.)


Avista Disappoints…

Question: If a SPAC announces their acquisition on a summer Friday, in the back half of August, after 5:00PM and without a follow-up conference call, do you think the SPAC team is eager to talk to investors? The obvious answer is no, but that’s just what Avista Public Healthcare Acquisition Corp. did this past Friday afternoon, and with good reason.

Avista announced they had entered into a merger agreement with Organogenesis,  a regenerative medicine company, for an anticipated initial enterprise value of approximately $673 million.  However, how Avista structured this transaction is not going to make investors happy.

Before we get into the details, you should now that investors will not get hurt in this transaction.  You will be able to redeem your shares.  However, investors aren’t investing in SPACs to “not get hurt”. You can invest in a Money Market or T-Bills for that.  SPAC investors are investing for a great return and unfortunately, the Avista deal is not going to provide that.

You can read the fine print on the announced deal here, but what you need to know is that Avista will be doing a PIPE with “affiliates of Avista,”  for $92 million ($46 at merger agreement and $46 million at closing) at effectively, $7.04.  Yes, you read that right. Due to that price, Avista expects full redemption of the Trust (obviously), but the real kicker is that the warrant strike is not being adjusted. So while at a $10.00 share price the warrants were $1.50 out-of-the-money ($11.50 strike), the warrants will now be ~$4.50 out-of-the-money (same strike of $11.50), making them far, far less valuable.

After reading the details, two things immediately come to mind:

One, if the Avista team ever wants to do another SPAC, they’re going to have to pay a LOT more for it. Any subsequent SPACs they attempt are probably going to require over-funding the trust or additional terms so that investors feel comfortable.   It’s a case of, “Fool me once…”

The second thing that comes to mind is a term that was included in the Crescent Funding SPAC.  If you remember, Crescent Funding Inc., filed for IPO back in January of 2018, but eventually withdrew their registration statement (most likely due to market conditions). However, the filing, which you can still find on SEC.gov, included a term for the warrants that stated Crescent would adjust the strike of the warrants in the event they:

“…issue additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at an issue price or effective issue price of less than $9.50 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the Market Value, and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the Market Value.”

It’s a great term and the take away here is, if we continue to see more business combinations structured like Avista, you can be sure investors will demand it.

 

Recent Posts
by Nicholas Alan Clayton on 2024-02-26 at 1:45pm

News and Rumors PR: Medtech firm Agiliti (NYSE:AGTI) has agreed to be acquired by an affiliate of private equity firm Thomas H. Lee Partners (THL) at $10 per share and an enterprise value of $2.5 billion. This represents a 43% premium over the company’s 90-day VWAP and returns it to 100% ownership by THL five...

by Nicholas Alan Clayton on 2024-02-26 at 7:42am

At the SPAC of Dawn The last week of February is to host a moderate amount of SPAC votes and also the potential for some market-moving data releases. Shareholders for five SPACs are to consider extensions this week and seven more SPACs have scheduled completion votes. But, among the more interesting events on the agenda...

by Kristi Marvin on 2024-02-24 at 11:45am

Terms Tracker for the Week Ending February 23, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. As expected, new issuance filings were quiet this week.  But, deal announcements were surprisingly active.  Four more SPACs announced combinations in a shortened holiday week...

by Nicholas Alan Clayton on 2024-02-23 at 2:26pm

Pyrophyte (NYSE:PHYT) faced a major regulatory setback for its combination with mining firm Sio Silica this week, but a recent analogous SPAC deal could provide some encouragement for a path forward. Sio Silica is working to develop a high-grade silica mine in the Vivian Sands outside Winnipeg, Canada and it inked the $708 million combination...

by Nicholas Alan Clayton on 2024-02-23 at 1:37pm

News and Rumors JD Supra: Securities class action lawsuits against SPACs and de-SPACs increased only slightly in 2023 with 27 after 2022 saw 24 and 2021 – 33. Lawsuits concerning the de-SPACing process itself dropped precipitously, however, representing just 21% of cases as compared to 69% in the previous two years and 80% in 2020....

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved